Absci Corp ABSI.OQ reported a quarterly adjusted loss of 24 cents per share for the quarter ended September 30, identical to the same quarter last year. The mean expectation of seven analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -25 cents to -18 cents per share.
Revenue rose 128.6% to $1.70 million from a year ago; analysts expected $1.75 million.
Absci Corp's reported EPS for the quarter was a loss of 24 cents.
The company reported a quarterly loss of $27.4 million.
Absci Corp shares had risen by 12.0% this quarter and gained 1.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 4.9% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Absci Corp is 7.00
This summary was machine generated from LSEG data November 12 at 03:32 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2024 | -0.21 | -0.24 | Missed |
Jun. 30 2024 | -0.19 | -0.22 | Missed |
Mar. 31 2024 | -0.21 | -0.22 | Missed |
Dec. 31 2023 | -0.25 | -0.25 | Met |
Comments